Hemispherx BioPharma, Inc 

(Public, AMEX:HEB)   Watch this stock   
Find more results for HEB
Nov 9, 2009
Q3 2009 Earnings Release
Sep 29, 2009
Maxim Group Conference
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -22764.71% -4610.94%
Operating margin -23405.88% -4834.34%
EBITD margin - -4659.24%
Return on average assets -51.03% -67.22%
Return on average equity -55.58% -75.20%
Employees 32 -

Address

1617 JFK Boulevard Suite 660
Philadelphia, PA 19103
United States - Map
+1-215-9880080 (Phone)
+1-215-9881739 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Hemispherx BioPharma, Inc discussed on blogs

Stock Market Analysis: Stocks to Buy 11/23/09 November 23, 2009 - tweid05@gmail.com (stockstobuy.org) - Stock Market Analysis - Nov 21, 2009

Hemispherx BioPharma, Inc discussions

  View all discussions »

Description

Hemispherx Biopharma, Inc. (Hemispherx) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer(adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.

Officers and directors

William A. Carter M.D.
Chairman of the Board, Chief Executive Officer
Age: 71
Bio & Compensation - Reuters
Charles T. Bernhardt CPA
Chief Financial Officer
Age: 47
Bio & Compensation - Reuters
Katalin Ferencz-Biro Ph.D.
Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 62
Bio & Compensation - Reuters
Robert Dickey IV
Senior Vice President
Age: 53
Bio & Compensation - Reuters
Wayne Springate
Vice President - Operations
Age: 38
Bio & Compensation - Reuters
Carol A. Smith Ph.D.
Vice President - Manufacturing Quality Assurance and Process Development
Age: 57
Bio & Compensation - Reuters
Russel J. Lander Ph.D.
Vice President - Quality Assurance
Age: 58
Bio & Compensation - Reuters
Ransom W. Etheridge
General Counsel
Portrait. Age: 69
Bio & Compensation - Reuters
Thomas K. Equels
Corporate Secretary, Director
Age: 57
Bio & Compensation - Reuters
David R. Strayer M.D.
Medical Director - Regulatory Affairs
Age: 63
Bio & Compensation - Reuters